Shanghai Junshi Biosciences Co., Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Rznomics To Partner With Lilly On

Akeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke

Leo Pharma has posted a strong set of financials for 2024, a year which saw the Danish drugmaker nail its three ambitions of increasing top-line growth, improving profitability and advancing in innova

Leo Pharma has had a busy start to 2025 on the business development front but its latest deal, a licensing pact for Shanghai Junshi Biosciences' PD-1 antibody toripalimab, has raised a few eyebrows. T